ABCL: Rega marang dodolan AbCellera Corp
Karl Hansen's team possesses impeccable scientific authority, although R&D return timelines remain lengthy. The current P/S multiple on this GURU.Markets chart visualizes the valuation trend, where 55.80 captures the magnitude of this parameter. AI technologies are accelerating antibody discovery for pharma behemoths, while the founder's control via super-voting shares ensures stable management of the AbCellera Biologics (ABCL) platform.
Rincian analitis perusahaan AbCellera Corp (ABCL)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas AbCellera Biologics|ABCL - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal AbCellera Bio|ABCL - Utang perusahaan|Rasio utang marang kapitalisasi buku AbCellera Corp|ABCL - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan AbCellera|Likuiditas darurat abcellera.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ABCL - Bathi resik perusahaan|Penghasilan resik sing dikarepake AbCellera Biologics|ABCL - Pangali P/E|Pangali Forward P/E AbCellera|ABCL - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan AbCellera Corp|ABCL - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan AbCellera|ABCL - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan abcellera.com|ABCL - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep AbCellera Biologics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:abcellera.com ABCL
The P/S ratio determines the market value of AbCellera Biologics (ABCL) relative to its annual revenue, allowing for an assessment of the asset's overvaluation without the influence of debt load. By analyzing the price-to-sales metric, an investor can see how the high reputation of Carl Hansen's team and the potential of the antibody platform justify current multiples given the prolonged payback cycles of scientific research.
Pesaing AbCellera Biologics
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|IMVT: Multiplikator P/S|KNSA (kiniksa.com) - Rasio rega marang pendapatan|GRFS (Grifols) - Multiplikator P/S|Kapitalisasi marang pendapatan Adaptive Biotech (ADPT)|Multiplikator P/S CLDX|AUPH - Rega marang dodolan|Rasio rega marang pendapatan BioCryst BCRX|veratx.com - Rasio rega marang pendapatan|DNTH - Rasio rega marang pendapatan|PHVS: Rasio rega marang pendapatan|TRML: Multiplikator P/S|Rega marang dodolan Precigen Corp (PGEN)|Rasio rega marang pendapatan Pharming Group N.V.|NKTR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S UPB|Multiplikator P/S Zenas Bio (ZBIO)|Immunome Corp - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan GOSS|KalVista Pharmaceuticals - Multiplikator P/S|SEPN: Rasio rega marang pendapatan|PVLA: Multiplikator P/S|SVRA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Rigel Pharmaceuticals Inc|Rega marang dodolan AnaptysBio Inc. ANAB|Rasio rega marang pendapatan Astria Therapeutics (ATXS)|Rasio rega marang pendapatan ENGN (engene.com)|Rasio rega marang pendapatan RAPT Therapeutics RAPT|Aerovate Therapeutics, Inc. (JBIO) - Rega marang dodolan|Aclaris - Multiplikator P/S|Multiplikator rega marang pendapatan Kyverna Therapeutics, Inc (KYTX)|TLSA: Multiplikator P/S|CABA - Koefisien rega marang pendapatan|VTYX (Ventyx Biosciences, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Theratechnologies, Inc. (THTX)|Rasio rega marang pendapatan Avalo Therapeutics Inc. (AVTX)|Koefisien rega marang pendapatan Eledon Pharmaceuticals, Inc|Multiplikator P/S AGEN (Agenus)|Multiplikator P/S climbbio.com CLYM|Zura Bio - Multiplikator P/S|ATYR: Rasio rega marang pendapatan|ADAG: Multiplikator P/S|Kapitalisasi marang pendapatan Ikena Oncology|Rasio rega marang pendapatan Shattuck Labs Inc|Rasio rega marang pendapatan EQ|Rasio rega marang pendapatan Connect Biopharma (CNTB)|IMUX: Rasio rega marang dodolan|Multiplikator P/S ATRA (Atara Bio)|Rasio kapitalisasi pasar marang pendapatan IFRX|X4 Pharmaceuticals - Multiplikator P/S|ACET - Multiplikator P/S|celularity.com (CELU) - Rasio rega marang pendapatan|INmune Bio Inc - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Multiplikator P/S SABS|Multiplikator P/S akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan QTTB|GeoVax Labs Inc - Multiplikator P/S|Koefisien rega marang pendapatan Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Carisma Therapeutics Inc.|Rasio rega marang pendapatan XTL Biopharmaceuticals Ltd.|Kapitalisasi marang pendapatan Bolt Bio (BOLT)|Kapitalisasi marang pendapatan HCWB (HCW Biologics Inc.)|Multiplikator P/S aptevotherapeutics.com (APVO)|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX: Rasio kapitalisasi marang pendapatan|GRI Bio - Multiplikator P/S|Rega marang dodolan XORTX Therapeutics Inc|HIND: Multiplikator P/S|Revelation Biosciences Corp (REVB) - Multiplikator P/S|INDP (Indaptus Therapeutics) - Multiplikator P/S|Rasio rega marang pendapatan SCNI|Multiplikator P/S CALI|Kapitalisasi marang pendapatan affimed.com AFMD|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Rega marang dodolan|IGMS - Rasio rega marang pendapatan|ITOS: Rasio rega marang pendapatan|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|TCBP (TC BioPharm (Holdings) Plc) - Rasio rega marang pendapatan|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
